Nature Reviews Drug Discovery, Published online: 11 November 2026; doi:10.1038/s41573-026-01551-y Over the past 25 years, kinase drug discovery has been one of the most active areas in pharmaceutical research and development. This article provides a comprehensive analysis of the kinase therapeutic landscape, covering drug platforms, new targeting approaches, the expanding target spectrum, approvals and clinical trends.
Aleksandr V. Sokolov, Doriano Fabbro, Stefan Knapp, Helgi B. Schiöth. The expansion of kinase drug discovery: new targets, platforms and indications. // Nature Reviews Drug Discovery. – 2026. – DOI: 10.1038/s41573-026-01551-y. – URL: https://www.nature.com/articles/s41573-026-01551-y
Aleksandr V. Sokolov, Doriano Fabbro, Stefan Knapp, & Helgi B. Schiöth (2026). The expansion of kinase drug discovery: new targets, platforms and indications. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01551-y
Aleksandr V. Sokolov, et al. “The expansion of kinase drug discovery: new targets, platforms and indications.” Nature Reviews Drug Discovery, 2026. doi:10.1038/s41573-026-01551-y.
@article{Sokolov2026,
title = {The expansion of kinase drug discovery: new targets, platforms and indications},
author = {Sokolov, Aleksandr V. and Fabbro, Doriano and Knapp, Stefan and Schiöth, Helgi B.},
journal = {Nature Reviews Drug Discovery},
year = {2026},
doi = {10.1038/s41573-026-01551-y},
url = {https://www.nature.com/articles/s41573-026-01551-y}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...